ClinicalTrials.govpublic full text
RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
met alterations, non small cell lung cancer, metex14 mutations, expanded access program, capmatinib, met tkis, ifct, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 889546
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.